1. Placental passage of the oxytocin antagonist atosiban
- Author
-
Valenzuela, Guillermo J., Craig, Jan, Bernhardt, Mark D., and Holland, Mary L.
- Subjects
Hormone antagonists -- Physiological aspects ,Premature labor -- Drug therapy ,Tocolytic agents -- Evaluation ,Health - Abstract
Atosiban appears to cross the placenta in only minimal amounts and seems to have no adverse effects on fetal oxygenation or on maternal blood loss after delivery. Atosiban is a new drug that relaxes the uterus. Eight women having an elective cesarean section at term were given an intravenous infusion of atosiban over 208 to 443 minutes prior to delivery. The average concentration of drug in the maternal uterine vein at delivery was 332 nanograms per milliliter but the concentration in the fetal umbilical vein was only 42 nanograms per milliliter. Longer infusion times did not increase atosiban levels in the fetus. Fetal blood pH, which is a measure of oxygenation, was similar to a group of 60 women having elective cesareans who did not receive atosiban. Medication to control blood loss was used more often in the atosiban group and one woman hemorrhaged.
- Published
- 1995